In this issue:
Morphea: disease activity and damage over time, and MRI vs. clinical assessment
Mycophenolate for treating morphea
Skin cancer/precancer risk after NB-UVB for vitiligo
Afamelanotide for erythropoietic protoporphyria in clinical practice
Laboratory safety of dupilumab in moderate-to-severe AD
Large tertiary centre’s experience with dapsone for dermatoses
Long-term outcomes of oxybutynin for primary hyperhidrosis
Importance of tranexamic acid in dermatology
Quality of systematic review reporting in dermatology journals
Bacterial skin infections in AD
Please login below to download this issue (PDF)